ESR1 and neoplasm: In 2010, Vranic et al. refined these criteria by requiring that over 90% of the tumor cells display these apocrine features, accompanied by a distinct immunohistochemical profile, i.e., the absence of ER/PR and positive androgen receptor (AR) expression [11].